Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Lexeo Therapeutics, Inc. Common Stock
1-25 of 360 filings
Recent SEC filings with analysis
- S-3Lexeo Therapeutics filed a new $300 million shelf registration statement on Form S-3 covering common stock, preferred stock, debt securities, warrants,…
- 8-KLexeo Therapeutics completed its acquisition of Mantle Therapeutics on September 29, 2026, making Mantle a wholly owned subsidiary under the merger agreement…
- 8-KLexeo Therapeutics (Nasdaq: LXEO) entered into a merger agreement on September 16, 2026 to acquire Mantle Therapeutics via its merger subsidiary, with Mantle…